Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 Disease.
Grüter T, Gaig C, Crijnen YS, Titulaer MJ, Sabater L, Heidbreder A, Dargvainiene J, Tietz A, Kovac S, Dik A, Erro ME, Lewerenz J, Kraft A, Seifert F, Höftberger R, Thaler FS, de Azevedo L, Wickel J, de Vries JM, Boon AJW, van Steenhoven RW, Gold R, Wandinger KP, Kuhlenbäumer G, Dalmau JO, Leypoldt F, Graus F, Ayzenberg I; Anti-IgLON5 Disease Study Group.
Grüter T, et al.
JAMA Neurol. 2025 Aug 4:e252574. doi: 10.1001/jamaneurol.2025.2574. Online ahead of print.
JAMA Neurol. 2025.
PMID: 40758377